Welcome to our dedicated page for Nevro news (Ticker: NVRO), a resource for investors and traders seeking the latest updates and insights on Nevro stock.
Nevro Corp. develops medical-device technologies for chronic pain treatment, centered on its proprietary 10 kHz Therapy and HFX spinal cord stimulation platform. Company updates commonly cover Senza, Senza II, Senza Omnia, HFX iQ, HFX Coach support services, and Nevrocloud physician insights for pain management and practice support.
News about Nevro also includes regulatory and product developments for spinal cord stimulation systems, clinical and publication updates for sacroiliac joint pain products such as the Nevro1 SI Joint Fusion System, and operating results for its U.S. and international business. Recurring corporate announcements include revenue guidance, preliminary financial results, employee inducement equity grants under NYSE rules, and other capital-structure or governance disclosures tied to its public-company status.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Nevro Corp. (NYSE: NVRO) reported its Q1 2023 financial results, showcasing a worldwide revenue of $96.3 million, up 10% from Q1 2022. Sales for the Painful Diabetic Neuropathy (PDN) indication surged 160% to approximately $15.6 million. U.S. revenue grew 12% to $82.3 million, with U.S. trial procedures up 9%.
However, the company faced a net loss of $36.3 million, compared to a $32.8 million loss in Q1 2022. The company initiated the launch of its AI-powered HFX iQ Spinal Cord Stimulation System and anticipates second quarter revenue guidance of $110 to $112 million. The full-year guidance maintains a revenue expectation of $445 to $455 million, representing 10% to 12% growth.
Nevro Corp. (NYSE: NVRO) announces the enrollment of the first patient in its Painful Diabetic Neuropathy (PDN) Sensory Study, marking a significant step as it is the first prospective randomized controlled trial aimed at assessing neurological function restoration in patients with intractable PDN. The study will include up to 236 patients and compares conventional treatment methods against 10 kHz Therapy combined with conventional management, facilitating optional crossover after 6 months.
The FDA has granted Breakthrough Device Designation, expediting the review for market application and expanding Nevro’s labeling. This designation aims to improve patient access to effective treatment options for debilitating conditions. The trial aims to confirm the benefits of the proprietary 10 kHz Therapy and may support better reimbursement strategies for PDN coverage.
Nevro Corp. (NYSE: NVRO), a leader in chronic pain treatment, has announced its participation in three significant investor conferences in May 2023. On May 10, CEO Kevin Thornal and CFO Rod MacLeod will present at the Bank of America 2023 Health Care Conference in Las Vegas at 5:00 pm PT. Following this, Rod MacLeod will present on May 16 at the JMP Securities Life Sciences Conference in New York at 11:00 am ET, and again on May 17 at the RBC Capital Markets Global Healthcare Conference at 11:30 am ET. Interested investors can access live webcasts and archived recordings from the events via Nevro's website. Nevro specializes in delivering innovative solutions for chronic pain, including the proprietary 10 kHz Therapy™ that benefits over 100,000 patients globally.